- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Inner nuclear layer.
Displaying page 1 of 1.
EudraCT Number: 2012-002628-34 | Sponsor Protocol Number: thorp8617-1 | Start Date*: 2012-08-29 | |||||||||||
Sponsor Name:Thor Petersen | |||||||||||||
Full Title: Optic neuritis and early treatment with methylprednisolone. | |||||||||||||
Medical condition: Optic neuritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000395-26 | Sponsor Protocol Number: GER-BGT-13-10586 | Start Date*: 2015-08-07 | |||||||||||
Sponsor Name:Biogen GmbH | |||||||||||||
Full Title: A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002654-95 | Sponsor Protocol Number: NET-MS | Start Date*: 2023-04-17 | ||||||||||||||||
Sponsor Name:FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS | ||||||||||||||||||
Full Title: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis | ||||||||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003501-25 | Sponsor Protocol Number: PQ-110-003 | Start Date*: 2019-02-28 | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due t... | |||||||||||||
Medical condition: Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002942-12 | Sponsor Protocol Number: P04737 | Start Date*: 2007-10-22 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis... | |||||||||||||
Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
